Anemia: Clinical Trials

4,692 trials for Anemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2686 completed, 535 unknown, 465 recruiting, 420 terminated. 1188 Phase 2, 994 Not applicable, 718 Phase 3, 600 Phase 1, 385 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21188Completed 634, Terminated 164, Recruiting 126, Unknown 103, Active not recruiting 66, Withdrawn 55, Not yet recruiting 38, Enrolling by invitation 2
Not applicable994Completed 601, Unknown 124, Recruiting 100, Terminated 52, Not yet recruiting 50, Active not recruiting 30, Withdrawn 30, Enrolling by invitation 4, Suspended 3
Phase 3718Completed 457, Terminated 81, Unknown 57, Recruiting 47, Active not recruiting 28, Not yet recruiting 24, Withdrawn 20, Suspended 3, Enrolling by invitation 1
Phase 1600Completed 339, Terminated 76, Recruiting 69, Active not recruiting 36, Unknown 36, Withdrawn 22, Not yet recruiting 19, Enrolling by invitation 2, Suspended 1
Phase 4385Completed 207, Unknown 74, Terminated 41, Recruiting 25, Not yet recruiting 18, Withdrawn 14, Active not recruiting 4, Enrolling by invitation 1, Suspended 1
Early Phase 148Completed 19, Recruiting 11, Unknown 5, Not yet recruiting 4, Terminated 4, Withdrawn 3, Active not recruiting 1, Enrolling by invitation 1

Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes
Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome)
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University102028-09-012026-11-12
Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease
KL003 Cell Injection - Sickle Cell Disease
Not applicableSuspendedInstitute of Hematology & Blood Diseases Hospital, China32028-03-012026-11-05
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria
Phase 3Not yet recruitingIndiana University15002028-01-012026-09-01
Methadone as an Alternative Treatment for Children Underdoing HSCT
PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia
Phase 3SuspendedUniversity of Texas Southwestern Medical Center602028-01-012025-10-23
Prenatal Transplantation for Fetuses With Fanconi Anemia
IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital
Phase 1 / Phase 2Not yet recruitingAgnieszka Czechowicz122028-01-012026-06-16
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome
Phase 2Not yet recruitingNovelMed Therapeutics122027-11-012026-04-13
Self-administered Acupressure in Patients With Sickle Cell Disease
Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand) - Sickle Cell Disease (SCD)
Not applicableNot yet recruitingUniversity of Cincinnati3002027-10-012026-10-15
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children
Not applicableNot yet recruitingConnecticut Children's Medical Center302027-09-012026-04-29
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia
Phase 2Not yet recruitingAnhui Provincial Hospital592027-08-012026-10-21
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Exa-cel - Sickle Cell Disease
Phase 3WithdrawnVertex Pharmaceuticals Incorporated2027-07-312026-03-25
Data Collection For Patients With Sickle Cell Disease
data collection - Data Collection, Sickle Cell Disease
Not yet recruitingM.D. Anderson Cancer Center5002027-04-062026-11-03
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
Roxadustat, Placebo - Myelodysplastic Syndromes
Phase 3Not yet recruitingKyntra Bio2012027-04-012026-07-23
A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
Imetelstat (7.1 mg/kg), Imetelstat (3.55 mg/kg) - MDS (Myelodysplastic Syndrome), MDS
Phase 4Not yet recruitingGeron Corporation1002027-03-012026-11-16
MBI for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease
Mindfulness-based intervention - Chronic Pain, Sickle Cell Disease
Not applicableNot yet recruitingUniversity of Illinois at Chicago482027-02-012026-09-21
A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.
FXS6837 Capsule - Paroxysmal Nocturnal Hemoglobinuria
Phase 3Not yet recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.202027-01-262026-11-04
Focused Ultrasound Neuromodulation for Chronic Pain
Focused PCM-Guided CMN LIFU, Unfocused Control LIFU - Chronic Pain, Sickle Cell Disease
Not applicableNot yet recruitingUniversity of Minnesota802027-01-042026-11-02
Mechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)
Music Therapy - Sickle Cell Disease
Not applicableNot yet recruitingUniversity Hospitals Cleveland Medical Center102027-01-022026-11-10
Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris
NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria
Phase 2Not yet recruitingNovelMed Therapeutics122027-01-012026-04-13
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Buprenorphine Buccal Film [Belbuca] - Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Phase 1Not yet recruitingNatasha Archer252027-01-012026-11-04
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
Cord Blood Red Blood Cells, Standard Adult Donor Red Blood Cells - Extremely Premature Infant, Anemia Neonatal
Not applicableNot yet recruitingHospital Clinic of Barcelona2802027-01-012026-11-09

Showing 20 of 4692. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (1124)  ·  Anemia, Iron-Deficiency (584)  ·  Anemia, Aplastic (357)  ·  Myelodysplastic Syndromes (344)  ·  Anemia, Refractory, with Excess of Blasts (320)  ·  beta-Thalassemia (264)  ·  Leukemia, Myeloid, Acute (250)  ·  Renal Insufficiency, Chronic (222)  ·  Thalassemia (221)  ·  Leukemia (220)  ·  Hemoglobinuria, Paroxysmal (190)  ·  Iron Deficiencies (187)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (178)  ·  Leukemia, Myelomonocytic, Chronic (150)

Broader conditions

Hemic and Lymphatic Diseases (4689)  ·  Hematologic Diseases (4556)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1850)  ·  Anemia, Hemolytic (1841)  ·  Genetic Diseases, Inborn (1648)  ·  Anemia, Hemolytic, Congenital (1530)  ·  Hemoglobinopathies (1419)  ·  Pathological Conditions, Signs and Symptoms (1183)  ·  Nutritional and Metabolic Diseases (1055)  ·  Bone Marrow Diseases (1035)  ·  Metabolic Diseases (984)  ·  Pathologic Processes (964)  ·  Iron Metabolism Disorders (732)  ·  Disease Attributes (664)

Interventions

Cyclophosphamide (178)  ·  Epoetin Alfa (166)  ·  fludarabine phosphate (130)  ·  Darbepoetin alfa (118)  ·  ferric carboxymaltose (116)  ·  Cyclosporine (115)  ·  fludarabine (112)  ·  Antilymphocyte Serum (101)  ·  ferrous sulfate (101)  ·  Whole-Body Irradiation (97)  ·  Busulfan (94)  ·  Hydroxyurea (90)  ·  Mycophenolic Acid (90)  ·  Iron (88)  ·  continuous erythropoietin receptor activator (68)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (124)  ·  Hoffmann-La Roche (105)  ·  Novartis Pharmaceuticals (83)  ·  Assistance Publique - Hôpitaux de Paris (78)  ·  Amgen (65)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (60)  ·  St. Jude Children's Research Hospital (55)  ·  Assiut University (50)  ·  Institute of Hematology & Blood Diseases Hospital, China (50)  ·  Alexion Pharmaceuticals, Inc. (48)  ·  Fred Hutchinson Cancer Center (42)  ·  Children's Hospital Medical Center, Cincinnati (41)  ·  National Cancer Institute (NCI) (41)  ·  Swiss Federal Institute of Technology (41)  ·  GlaxoSmithKline (37)

Countries

United States (1923)  ·  France (388)  ·  China (353)  ·  United Kingdom (331)  ·  Italy (304)  ·  Germany (267)  ·  Canada (243)  ·  Spain (195)  ·  Egypt (139)  ·  Netherlands (126)  ·  Turkey (Türkiye) (125)  ·  Belgium (122)  ·  Australia (116)  ·  Brazil (111)  ·  South Korea (111)

Top investigators

John F Tisdale, M.D. (16)  ·  Ariel Koren, MD (13)  ·  Swee Lay Thein, M.D. (12)

Results publications

PMID 36005278, PMID 36791280, PMID 41114449, PMID 34932836, PMID 26965694, PMID 37975597, PMID 33783815, PMID 36240296, PMID 38780066, PMID 34724566, PMID 37254256, PMID 29958797, PMID 38775255, PMID 29674506, PMID 40277027, PMID 40569673, PMID 41026975, PMID 42133908, PMID 23343061, PMID 23343062, PMID 23738544, PMID 26589907, PMID 29419434, PMID 31413088, PMID 34175041, PMID 34219224, PMID 36749544, PMID 38363466, PMID 40359056, PMID 40576086, PMID 18328118, PMID 19208097, PMID 20175775, PMID 21982521, PMID 24916507, PMID 26504182, PMID 30504345, PMID 30957581, PMID 31203241, PMID 31974203, PMID 32499241, PMID 32678434, PMID 33661274, PMID 34362786, PMID 34710946, PMID 34922648, PMID 36594181, PMID 36860093, PMID 36975201, PMID 37651553

NIH funding

2017 (24), 2023 (24), 2019 (23), 2016 (21), P30CA015704 (21), 2014 (17), 2015 (12), P30CA006973 (12), 2018 (11), 2005 (9), 2008 (9), 2009 (8), P30CA043703 (8), U01HL065238 (8), U54HL070587 (8)